# Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

> **NCT04989946** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Wisconsin, Madison** · enrollment: 60 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Degarelix
- **BIOLOGICAL:** pTVG-AR
- **DRUG:** Nivolumab
- **DRUG:** Cemiplimab
- **DRUG:** Fianlimab
- **DRUG:** FLT PET/CT

## Key facts

- **NCT ID:** NCT04989946
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-16
- **Primary completion:** 2026-12
- **Final completion:** 2028-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-28

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04989946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04989946, "Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04989946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*